anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably to ophthalmology, and can be used for treatment of neovascular terminal glaucoma. Patient receives intravenous transfusion of photosensitiser (PS) of chlorin series in amount of 0.8-1.1 mg/kg during 7-10 minutes. 5 minutes later eye's musculi recti must be exposed to laser light through conjunctiva at places of their insertion onto sclera, with the device, fixed to projection places of insertions in each quadrant. Light's wavelength must comply with maximum absorption of optical emission by (PS), radiation density rate must be 200-250 J/cm2. ^ EFFECT: method allows to avoid surgery, provides possibility to dose laser impact at eye's musculi recti, provides persistent depression of intraocular pressure and partial regress of iris neovascular net. ^ 1 tbl, 1 ex
The disclosure comprises a first housing body, a first barrel portion, a second barrel portion, a PH value sensing portion, and a remote monitoring portion. The first and second barrel portions are adjacently connected in the housing body. The first barrel portion has a first fastening end portion and a first accommodation space. The fastening end portion extends out of the housing body to provide the PH value sensing portion to insert and connect to the first accommodation space, thereby further sensing the fluid stored in the first accommodation space. A PH value signal is therefore obtained and wirelessly transmitted to the remote monitoring portion. The second barrel portion has an inspection opening and a second accommodation space. The fluid stored in the first accommodation space reaches a second height and flows into the second accommodation space. Moreover, the fluid is drained while reaching a third height in the second accommodation space. The inspection opening is provided for extracting the fluid inside the second accommodation space. Therefore, the disclosure has advantages of remotely monitoring the PH value of drained body fluid and inspecting the opening to sample the fluid.
An anti-skin photoaging composition and use thereof. Said composition comprises (0.1 to 100) parts by weight of component A and (1000 to 20000) parts by weight of component B. The component A comprises at least one of carnosic acid, a pharmaceutically acceptable salt thereof or a solvate thereof, and the component B comprises at least one of protopanoxadiol, a pharmaceutically acceptable salt thereof or a solvate thereof. The anti-skin photoaging composition has effects of photoaging resistance and aging resistance. Carnosic acid and protopanoxadiol in the composition act on different antioxidant channels and sites, and achieve a better photoaging resistance effect by means of a synergistic effect. Therefore, the composition is more valuable for promotion and application in skin care products and other products.
Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder predominantly characterised by periodic fever, abdominal pain, and joint manifestations. It can exhibit various atypical presentations. However, cases of FMF concurrently presenting with chronic thrombosis and myositis have not been previously reported. A 41-year-old male presented with alternating severe bilateral leg pain, stiffness, and localised swellings without fever or abdominal symptoms. His history included inflammatory joint pain treated with prednisolone. Physical examination revealed leg pain, limited ankle joint movement, and tender swellings in thighs, forearms, and feet. Collateral abdominal veins were also observed. Unresponsive to prednisolone and colchicine, the patient underwent MRI, revealing muscle inflammation in both legs and thighs and chronic thrombosis in the infrarenal inferior vena cava. Genetic testing confirmed the heterozygotic M694V mutation, diagnosing an atypical FMF. This case uniquely showcases coexisting myositis and chronic thrombosis in FMF. Myalgia is common in FMF, with M694V mutation associated with severe muscular symptoms. The lack of fever and myositis findings differentiate our case from protracted febrile myalgia syndrome. FMF's chronic inflammatory state is known to influence thrombosis risk, and our findings align with this association. Chronic thromboembolism and myositis together signify an unusual clinical presentation of FMF. This case highlights the potential for FMF to present with complex manifestations beyond the conventional symptoms. Myositis and vascular involvement should prompt consideration of FMF diagnosis when combined with patient history, clinical features, and laboratory results. These rare associations underscore the need for further research to enhance understanding of FMF's diverse clinical spectrum.
The invention discloses a Chinese medicine, and particularly relates to a medicament for treating psoriasis. The Chinese medicine comprises the following components by weight: 10 grams of bezoar, 20 grams of sandalwood, 15 grams of dragon's blood, 20 grams of dark plum fruit, 20 grams of bulbus fritilariae, 30 grams of pangolin scales, 20 grams of golden thread, 30 grams of scorpion and 10 grams of buffalo horn. A preparation method comprises the following steps of: removing impurities in the medicaments, washing by clear water, roasting over slow fire, crushing and grinding to form fine powder, mixing and stirring uniformly, and filling into capsules. Due to the adoption of nine high-efficiency Chinese herbal medicines, the medicament has the effects of clearing heat and detoxicating, softening hard lumps and eliminating stagnation, moistening dryness and treating pyogenic infection, promoting blood circulation and dispelling wind and regulating qi and spleen. By the medicament, the microcirculation of skin at lesion site of infection can be improved, trace elements can be replenished directly, the photosensitization of the skin can be increased, the activity of the lesion site of infection can be activated, and the synthesis of the skin can be promoted. In addition, the medicament has a scientific and reasonable formula, good in matching of medicines, small in using amount, good in curative effect and obvious in treatment effect, and does not have toxic nor side effect.
FIELD: veterinary science. SUBSTANCE: preparation has dioxydin at amount 0.74-0.79% of volume and neomycin sulfate at amount 1.22-1.26% of volume and gelatin-glycerol base - the rest. Ready preparation made as pessary is administrated in cows by untrauterine route depending on severity of pathological process at amount 3-5 things per a single administration, every 8-12 h, up to uterus cervix close. Preparation is administrated once for prophylaxis. EFFECT: enhanced effectiveness of preparation. 1 tbl
FIELD: medicine, experimental phthisiology. SUBSTANCE: method involves administration of taufon on the background of treatment with isoniazide being taufon is administrated in the dose 15 mg/kg every day for two months, not less. This invention promotes to the enhancement of efficiency of treatment of experimental tuberculosis. Invention can be used in treatment of experimental tuberculosis. EFFECT: improved method of treatment, expanded assortment of preparation used. 2 cl, 3 tbl
Participants will perform a single session with a longer foam rolling volume. The protocol will be 3 sets of 60 seconds, with between-sets intervals of 30 seconds and a standardized command to the participant to perform the highest pressure possible. The speed will be controlled through metronome (30 bpm). The foam rolling will be performed with the foam roller placed under the plantar flexors and Achilles tendon in a sitting position, with hands supported to the ground, keeping the body out of contact with the ground, with the unassessed leg crossed above the leg of interest. A standard device (smooth foam roller) with dimensions of 30 cm x 15 cm will be used.
The present invention is directed to carboxylic acid and ester moieties that are attached to a carbon chain that is between 2 and 24 carbons in length wherein, the chain contains at least one dioxanone ring system, said dioxanone being formed from two adjacent carbons in the chain and/or at least one carbon in the chain is substituted with a pendant dioxanone ring system. In preferred embodiments, the carbon chain is a fatty acid residue. The carbons of said chain can be optionally substituted, saturated or unsaturated. When two or more said ester moieties are present, the invention is directed to a polyester such as a triglyceride, that contains multiple carbon chains wherein each chain is independently derivatized such that the triglyceride contains at least one dioxanone ring system, said dioxanone being formed from two adjacent carbons in at least one of said chains. The present invention is also directed to a method of preparing a dioxanone containing composition of fatty acid derivative. The present invention is also directed to coating formulations and polymers that utilize a dioxanone containing composition or fatty acid derivative, and methods of making such coatings and polymers.
Obesity is a risk factor for anxiety and depression. Obesity is also a risk factor for severe COVID-19 disease and therefore may have contributed to adverse mental health outcomes in this vulnerable population during the COVID-19 pandemic. We compare the trajectory of mental health outcomes of people with obesity with normal-weight people before and during the COVID-19 pandemic using nationally representative individual-level longitudinal data from the National Health Interview Survey and Difference-in-Difference regressions. Our results indicate that severe anxiety increased by 2.75 (95% CI: 0.0056-0.0494; p-value 0.014) percentage points, representing a 31.3% relative increase, and anxiety-related prescription drug usage increased by 2.75 (95% CI: 0.0076-0.0473; p-value<0.01) percentage points, representing a 19.2% relative increase among people with obesity, compared to normal-weight people. We conclude that people with obesity experienced an increase in the incidence of severe anxiety and anxiety-related prescription drug usage during the COVID-19 pandemic, which was not observed among normal-weight individuals. Furthermore, women, less-educated, and rural residents with obesity disproportionately bore the burden of the pandemic.
Recent studies have shown the crucial role of podocyte injury in the development of diabetic kidney disease (DKD). Deubiquitinating modification of proteins is widely involved in the occurrence and development of diseases. Here, we explore the role and regulating mechanism of a deubiquitinating enzyme, OTUD5, in podocyte injury and DKD. RNA-seq analysis indicates a significantly decreased expression of OTUD5 in HG/PA-stimulated podocytes. Podocyte-specific Otud5 knockout exacerbates podocyte injury and DKD in both type 1 and type 2 diabetic mice. Furthermore, AVV9-mediated OTUD5 overexpression in podocytes shows a therapeutic effect against DKD. Mass spectrometry and co-immunoprecipitation experiments reveal an inflammation-regulating protein, TAK1, as the substrate of OTUD5 in podocytes. Mechanistically, OTUD5 deubiquitinates K63-linked TAK1 at the K158 site through its active site C224, which subsequently prevents the phosphorylation of TAK1 and reduces downstream inflammatory responses in podocytes. Our findings show an OTUD5-TAK1 axis in podocyte inflammation and injury and highlight the potential of OTUD5 as a promising therapeutic target for DKD.
Meningococcal disease is a potentially life-threatening bacterial infection. The disease most commonly is expressed as either meningococcal meningitis, an inflammation of the membranes surrounding the brain and spinal cord, or meningococcemia, the presence of bacteria in the blood. The most common symptoms include high fever, headache, neck stiffness, confusion, nausea, vomiting, lethargy, and rash. If not treated the disease can progress rapidly and can lead to shock and death, often within hours of the onset of symptoms. Neisseria meningitidis capsular polysaccharides are poor immunogens. However, conjugation of bacterial polysaccharides to immunogenic carrier proteins generally results in conjugates that induce strong anti-polysaccharide T-helper cell dependent immune responses, creating a longer-lasting immune response and thus protection against meningococcal infection. This study compares safety and antibody production induced by one intramuscular injection of either NmVac4-A/C/Y/W-135-DT or a licensed meningococcal A/C/Y/W-135-DT conjugate vaccine. Participants will attend a screening visit up to 4 weeks prior to Day 0, then will attend study visits for 8 weeks. There will be a study phone call at Days 2-3, then a post-study telephone call to subjects to assess safety at 26 weeks.
PROBLEM TO BE SOLVED: To obtain an antiosteoporotic agent easily and commonly usable and capable of manifesting mild therapeutic and preventing effects by including a trehalose as an active ingredient. SOLUTION: This antiosteoporotic agent preferably as a preventing agent for osteoporosis, a therapeutic agent for the osteroporosis and a differentiation induction inhibitor of osteoclasts is obtained by including >=0.1% (wt./wt.) of a trehalose as an active ingredient and preferably another ingredient for facilitating the ingestion of the trehalose. In this case, a raw material and/or a material used for foods, e.g. water, an alcohol, a starch, a protein or a fiber may be formulated as the ingredient for facilitating the ingestion of the trehalose. Furthermore, a healthy food material such as a glucide for proliferating bifidus bacteria or a milk powder can be formulated. The trehalose is daily ingested so as to provide preferably 1-50 g/adult/day intake or ingested 1-5 times/week.
the specific aims of this research are 1) To develop and refine, with user feedback, a cognitive behavioral therapy-based text-messaging intervention (TXT-CBT) for HIV-infected adults with opioid dependence; 2) To conduct a pilot randomized clinical trial to assess the feasibility of recruiting and retaining individuals for a large scale study and to determine the effect size of TXT-CBT over and above standard care (SC) on opioid use, HIV medication adherence, and healthcare outcomes. Both SC and SC+TXT-CBT participants will be assessed at baseline, treatment-end, and 12 weeks post-treatment; and 3) To examine potential mechanisms of action of TXT-CBT, including self-efficacy, affect regulation, and social support. The investigators hypothesize that TXT-CBT delivered in conjunction with SC will produce greater reductions in opioid use and HIV-risk behaviors, and will improve HIV treatment regimen adherence, relative to MM alone. Further, the investigators expect that SC+TXT-CBT will facilitate greater changes in negative affect, self-efficacy, and social support, and these changes will be associated with substance use outcomes. TXT-CBT incorporates specific substance- and adherence-focused cognitive therapy techniques with a concurrent emphasis on reducing HIV-risk behaviors. By providing support to maximize HIV treatment regimen adherence, coupled with coping skills to address withdrawal symptoms and stress, two important factors in opioid relapse, TXT-CBT may provide a promising, cost-effective, and easily deployable augmenting strategy for the treatment of opioid users who are HIV-infected.
Durg：RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Durg ：Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
In patients with type 2 diabetes whose glycemic control is not accomplished with Metformin alone, there are several options for additional hypoglycemic agent. As per recent National guidelines at least three "second line" agents can be added to metformin: thiazolidinediones, Lantus insulin, and DPP4 inhibitors. All three approaches have been proven to help accomplishing goals of therapy for glycemic control (HbA1c\<7%) in clinical trials. Whether one approach is superior to the other in improving associated non-glycemic metabolic abnormalities and risk for future morbidity and mortality in patients with type 2 diabetes remains a matter of intense debate. Among these abnormalities, excessive triglyceride content in the liver (fatty liver or liver steatosis) is a major predictor of risk for non-alcoholic steato-hepatitis (NASH) and liver cirrhosis. Fatty liver is highly prevalent in patients with type 2 diabetes. There are no clinical studies done to determine if any of these three therapeutic options is superior at reducing the liver triglyceride content in patients with type 2 diabetes and fatty Liver. Therefore, in this study we propose to measure and compare the effects on liver triglyceride content when either pioglitazone, lantus insulin, or DPP4 inhibitors are added to metformin in patients with poorly controlled type 2 diabetes (HbA1c\>7.6%) and fatty liver (presence of "bright" liver in abdominal ultrasound). The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.
TRUDHESA, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery vasospasm. Myocardial, peripheral vascular, and colonic ischemia have been reported with dihydroergotamine mesylate.

Dihydroergotamine mesylate associated vasospastic phenomena may also cause muscle pains, numbness, coldness, pallor, and cyanosis of the digits. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. TRUDHESA should be discontinued immediately if signs or symptoms of vasoconstriction develop.

Patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome, following the use of any 5-HT agonist, including TRUDHESA, should be evaluated by a healthcare provider.
Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
Chitosan is a polymeric polysaccharide with widely application. At present, commercialized chitosan obtained by deacetylating chitin with acid-alkali method. The homogeneity of the molecular weight of chitosan is difficult to adjust due to the low homogeneity of chitosan itself and the degradation effect of the extraction process. And the single source of raw material has limited the further development of chitosan. In this study, diatoms were used as the source of chitosan extraction through alkalization freeze-thaw method, and response surface methodology was also used to optimize the best preparation conditions of diatom chitosan. The extracted chitosan from diatom was β-type chitosan with low molecular weight, great homogeneity. Diatom chitosan was able to reduce blood loss and clotting time >30 % in vivo experiment compared to control. The hemolysis rate of diatom chitosan was lower than 1 %, and the survival rate was higher than 95 % when co-cultured with L929 cells. Diatom chitosan with 0.005 % could inhibit E. coli and S. aureus by >90 %. Considering the large-scale cultivation properties of diatom, the extraction of diatom chitosan based on alkalization freeze-thaw method will provide a viable solution for obtaining β-chitosan with homogeneity on a large scale.
Photodynamic therapy (PDT) has significant advantages in the treatment of malignant lung tumors. The research on the mechanism of PDT mediated by hematoporphyrin derivatives (HPD) and its cytotoxic effects on lung cancer cells has primarily focused on lung adenocarcinoma cells. However, the impact of HPD-PDT on lung squamous cell carcinoma has not been thoroughly studied. This study aimed to investigate the effects of 630 nm laser on apoptosis, metastasis, invasion, and epithelial-mesenchymal transition (EMT) in human lung squamous cell carcinoma H520 cells mediated by HPD. H520 cells were divided into four groups: control group, photosensitizer group, irradiation group, and HPD-PDT group. Cell proliferation was assessed using CCK8 assay; cell apoptosis was detected by Hoechst 33258 staining and flow cytometry; cell migration and invasion abilities were evaluated using wound-healing and invasion assays; and protein and mRNA expressions were analyzed by Western blot and reverse transcription-polymerase chain reaction (RT-PCR) respectively. Results showed that HPD-PDT significantly inhibited cell proliferation, promoted apoptosis (P < 0.05), suppressed cell migration and invasion (P < 0.05), decreased Bcl-2 mRNA expression, and increased Bax and Caspase-9 mRNA expression(P < 0.05). Western blotting analysis indicated increased expression of Bax, Caspase-9, and E-cadherin, and decreased expression of Bcl-2, N-cadherin, and Vimentin (P < 0.05). In conclusion, 630 nm laser mediated by HPD promoted cell apoptosis via upregulation of Bax and caspase-9, and downregulation of Bcl-2, and inhibited cell migration and invasion by regulating EMT in H520 cells.
PURPOSE: An agent for treating inflammatory bowel disease is provided to be used in manufacturing a drug or food. CONSTITUTION: A composition for treating inflammatory bowel diseases contains aloin as an active ingredient. The active ingredient is contained in 0.001-15 weight%. The composition is a pharmaceutical composition and a food composition. The food composition is beverage. The composition also contains 0.001-15 weight% of aloe gel as an active ingredient.
PROBLEM TO BE SOLVED: To obtain a preparation for oral use with masked bitter taste and having good administration feeling and taste. SOLUTION: This composition contains one or more kinds of gastrointestinal medicines selected from tiquizium bromide, scopolia extract, butylscropolamine bromide and timepidium bromide and stevia which is a sweatener ingredient as active ingredients. Effective blend ratio of stevia is 5-100mg, preferably 10-50mg/day.adult. Blend amount of stevia is 0.1-10 pts.wt., preferably 0.5-3 pts.wt. based on 1 pt.wt. tiquizium bromide, though it differs by component of gastrointestinal medicines. As necessary, other well-known additive is blended and the blend can be contained in preparation for oral uses such as granules, particles, powdery preparation, capsule, tablet, chewable preparation, dry syrup, liquid agent, etc.  The preparation is relatively stable to heat and acid and has high safety and can be used without anxiety and has mild quality of sweetness, slight after-taste and non-fermentanting property and causes no browning by heat treatment.